CD274 and gastric cancer: Based on these results and the observation shown in the current study, two clinical trials have been planned (Imugene Limited, Sydney, Australia) to assess the following: (1) HER-Vaxx in combination with chemotherapy or the anti-PD-1 antibody pembrolizumab in patients with Her-2/neu-overexpressing gastric cancer who have failed treatment with trastuzumab, and (2) HER-Vaxx in combination with chemotherapy +/− the anti-PD-L1 antibody avelumab in patients with Her-2/neu-overexpressing gastric cancer.